)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
HLB
HLB (028300) investor relations material
HLB Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
9M 2026 revenue rose to ₩72.7bn from ₩55.5bn YoY, while operating loss was ₩73.2bn; net loss narrowed to ₩142.1bn from ₩206.1bn.
LYRFIGTU received U.S. FDA approval in September for second-line FGFR2 fusion or rearrangement cholangiocarcinoma; lirafugratinib commercialization is moving forward.
Financial highlights
9M revenue ₩72.67bn vs ₩55.51bn YoY; gross profit ₩31.72bn vs ₩17.05bn.
9M operating loss ₩73.22bn vs ₩74.85bn; net loss ₩142.10bn vs ₩206.11bn; basic and diluted EPS were both -₩1,001 vs -₩1,487.
Q3 revenue was ₩25.98bn vs ₩22.11bn YoY; Q3 net loss was ₩20.81bn vs ₩76.44bn.
Operating cash outflow was ₩56.70bn; cash and cash equivalents were ₩41.40bn at quarter-end vs ₩40.98bn at FY 2025-end.
Outlook and guidance
LYRFIGTU is planned for global commercialization and launch following FDA approval; an EMA marketing application was filed in September.
Rivoceranib plus camrelizumab liver-cancer NDA resubmission followed a third FDA CRL; a further resubmission was filed Oct. 9, after quarter-end.
ITI-5000 for triple-negative breast cancer and ITI-9001 for Japanese cedar allergy entered Phase 1; additional FGFR2-altered solid-tumor trials are underway.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from HLB
- Revenue up 58.8%, operating loss narrows, and focus remains on oncology drug launches.028300
Q4 2024 - Revenue up 23.6% YoY, operating loss narrows, merger boosts R&D and pipeline focus.028300Q4 2025
- Revenue fell and losses widened as R&D spending rose, with focus shifting to global drug commercialization.028300Q3 2025
- Heavy losses persist as revenue drops and R&D costs remain high; outlook hinges on drug approvals.028300Q2 2025
- Merger completed to streamline R&D; H1 2026 revenue KRW 46.7B, net loss persists.028300Q2 2026
- Q1 2026 posted a net loss of KRW 38.0 billion amid ongoing R&D and business restructuring.028300Q1 2026
- H1 2024 saw lower revenue, ongoing losses, and a strategic focus on oncology drug approval.028300Q2 2024
- Q3 2024 saw flat sales, narrowed losses, and a strategic focus on oncology drug approval.028300Q3 2024
- Q1 2025 revenue fell to KRW 17.66B with a net loss of KRW 68.92B amid high R&D costs.028300Q1 2025
HLB
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)